Olaharski A - Search Results

1

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.

Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, Cianchetta G, Cai Z, Zhou D, Cui D, Chen P, Straley K, Tobin E, Wang F, David MD, Penard-Lacronique V, Quivoron C, Saada V, de Botton S, Gross S, Dang L, Yang H, Utley L, Chen Y, Kim H, Jin S, Gu Z, Yao G, Luo Z, Lv X, Fang C, Yan L, Olaharski A, Silverman L, Biller S, Su SM, Yen K. Popovici-Muller J, et al. Among authors: olaharski a. ACS Med Chem Lett. 2018 Jan 19;9(4):300-305. doi: 10.1021/acsmedchemlett.7b00421. eCollection 2018 Apr 12. ACS Med Chem Lett. 2018. PMID: 29670690 Free PMC article.

2

Preclinical toxicology profile of squalene epoxidase inhibitors.

Nagaraja R, Olaharski A, Narayanaswamy R, Mahoney C, Pirman D, Gross S, Roddy TP, Popovici-Muller J, Smolen GA, Silverman L. Nagaraja R, et al. Among authors: olaharski a. Toxicol Appl Pharmacol. 2020 Aug 15;401:115103. doi: 10.1016/j.taap.2020.115103. Epub 2020 Jun 6. Toxicol Appl Pharmacol. 2020. PMID: 32522582

3

Pharmacological inhibition of polo like kinase 2 (PLK2) does not cause chromosomal damage or result in the formation of micronuclei.

Fitzgerald K, Bergeron M, Willits C, Bowers S, Aubele DL, Goldbach E, Tonn G, Ness D, Olaharski A. Fitzgerald K, et al. Among authors: olaharski a. Toxicol Appl Pharmacol. 2013 May 15;269(1):1-7. doi: 10.1016/j.taap.2013.02.012. Epub 2013 Mar 1. Toxicol Appl Pharmacol. 2013. PMID: 23466428

4

The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.

Colleton C, Brewster D, Chester A, Clarke DO, Heining P, Olaharski A, Graziano M. Colleton C, et al. Among authors: olaharski a. Toxicol Pathol. 2016 Apr;44(3):458-66. doi: 10.1177/0192623315617562. Toxicol Pathol. 2016. PMID: 27006130

5

Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis.

Ness D, Ren Z, Gardai S, Sharpnack D, Johnson VJ, Brennan RJ, Brigham EF, Olaharski AJ. Ness D, et al. Among authors: olaharski aj. PLoS One. 2013 Jun 14;8(6):e66164. doi: 10.1371/journal.pone.0066164. Print 2013. PLoS One. 2013. PMID: 23799078 Free PMC article.

6

Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat.

Fielden MR, Adai A, Dunn RT 2nd, Olaharski A, Searfoss G, Sina J, Aubrecht J, Boitier E, Nioi P, Auerbach S, Jacobson-Kram D, Raghavan N, Yang Y, Kincaid A, Sherlock J, Chen SJ, Car B; Predictive Safety Testing Consortium, Carcinogenicity Working Group. Fielden MR, et al. Among authors: olaharski a. Toxicol Sci. 2011 Nov;124(1):54-74. doi: 10.1093/toxsci/kfr202. Epub 2011 Aug 2. Toxicol Sci. 2011. PMID: 21813463

7

In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates.

Olaharski AJ, Uppal H, Cooper M, Platz S, Zabka TS, Kolaja KL. Olaharski AJ, et al. Toxicol Lett. 2009 Jul 24;188(2):98-103. doi: 10.1016/j.toxlet.2009.03.012. Epub 2009 Mar 25. Toxicol Lett. 2009. PMID: 19446241

8

Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat.

Fielden MR, Nie A, McMillian M, Elangbam CS, Trela BA, Yang Y, Dunn RT 2nd, Dragan Y, Fransson-Stehen R, Bogdanffy M, Adams SP, Foster WR, Chen SJ, Rossi P, Kasper P, Jacobson-Kram D, Tatsuoka KS, Wier PJ, Gollub J, Halbert DN, Roter A, Young JK, Sina JF, Marlowe J, Martus HJ, Aubrecht J, Olaharski AJ, Roome N, Nioi P, Pardo I, Snyder R, Perry R, Lord P, Mattes W, Car BD; Predictive Safety Testing Consortium; Carcinogenicity Working Group. Fielden MR, et al. Among authors: olaharski aj. Toxicol Sci. 2008 May;103(1):28-34. doi: 10.1093/toxsci/kfn022. Epub 2008 Feb 14. Toxicol Sci. 2008. PMID: 18281259

9

Biomarkers of carcinogenicity and their roles in drug discovery and development.

Guan P, Olaharski A, Fielden M, Roome N, Dragan Y, Sina J. Guan P, et al. Among authors: olaharski a. Expert Rev Clin Pharmacol. 2008 Nov;1(6):759-71. doi: 10.1586/17512433.1.6.759. Expert Rev Clin Pharmacol. 2008. PMID: 24410606

10

Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors.

Olaharski AJ, Bitter H, Gonzaludo N, Kondru R, Goldstein DM, Zabka TS, Lin H, Singer T, Kolaja K. Olaharski AJ, et al. Toxicol Sci. 2010 Nov;118(1):266-75. doi: 10.1093/toxsci/kfq258. Epub 2010 Sep 1. Toxicol Sci. 2010. PMID: 20810542

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters